Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis

Sylvain Mathieu,1,2 Marion Couderc,1,2 Baptiste Glace,1,2 Bruno Pereira,2,3 Anne Tournadre,1,2 Jean-Jacques Dubost,1,2 Martin Soubrier1,21Department of Rheumatology, Gabriel-Montpied Hospital, 2Faculty of Medicine, University Clermont 1, 3Délégation de la Recherche Clinique, Ga...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mathieu S, Couderc M, Glace B, Pereira B, Tournadre A, Dubost JJ, Soubrier M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/10caf1be94814f1781ec7ff2e9f6d82c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:10caf1be94814f1781ec7ff2e9f6d82c
record_format	dspace
spelling	oai:doaj.org-article:10caf1be94814f1781ec7ff2e9f6d82c2021-12-02T08:16:22ZEffects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis1177-54751177-5491https://doaj.org/article/10caf1be94814f1781ec7ff2e9f6d82c2013-12-01T00:00:00Zhttp://www.dovepress.com/effects-of-6-months-of-abatacept-treatment-on-aortic-stiffness-in-pati-a15137https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Sylvain Mathieu,1,2 Marion Couderc,1,2 Baptiste Glace,1,2 Bruno Pereira,2,3 Anne Tournadre,1,2 Jean-Jacques Dubost,1,2 Martin Soubrier1,21Department of Rheumatology, Gabriel-Montpied Hospital, 2Faculty of Medicine, University Clermont 1, 3Délégation de la Recherche Clinique, Gabriel-Montpied Hospital, Clermont-Ferrand, FranceBackground: Systemic inflammation plays an important role in the increased cardiac risk observed in rheumatoid arthritis (RA). Effective control of inflammation and disease activity may be of benefit in reducing cardiovascular risk in RA patients.Objective: Our study was conducted in patients with active RA to investigate the effects of 24-week abatacept treatment on aortic stiffness measured by pulse wave velocity (PWV).Results: The study included 21 patients, of whom 17 were females, with a mean age of 65.2±13.7 years. Ten patients had positive rheumatoid factors, 16 positive anti-citrullinated protein antibodies, and 19 presented an erosive form of RA. Sixteen patients were nonresponders to anti-tumor necrosis factor-alpha treatments. After 6 months of abatacept treatment, there was a significant increase in PWV levels (9.8±2.9 versus 8.5±3.9 m/second; P=0.02). A nonsignificant increase in total cholesterol and low-density lipoprotein cholesterol was observed. There was also a significant increase in high-density lipoprotein cholesterol levels, which led to a nonsignificant decrease in atherogenic index. The improvement in disease activity was significant, and there was a decrease of systemic inflammatory parameters, but without reaching statistical significancy. Changes in PWV were significantly correlated with changes in Disease Activity Score on 28 joints based on erythrocyte sedimentation rate (r=0.46; P=0.035) and in high-density lipoprotein cholesterol (r=-0.38; P=0.046). No correlation was observed with changes in C-reactive protein and in other parameters of lipid profile or in steroid dose.Conclusion: The worsening of aortic stiffness found after 6 months of abatacept therapy might be due to an insufficient decrease in systemic inflammation.Keywords: arterial stiffness, cardiovascular risk markers, systemic inflammation, atherogenic indexMathieu SCouderc MGlace BPereira BTournadre ADubost JJSoubrier MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 259-264 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Mathieu S Couderc M Glace B Pereira B Tournadre A Dubost JJ Soubrier M Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
description	Sylvain Mathieu,1,2 Marion Couderc,1,2 Baptiste Glace,1,2 Bruno Pereira,2,3 Anne Tournadre,1,2 Jean-Jacques Dubost,1,2 Martin Soubrier1,21Department of Rheumatology, Gabriel-Montpied Hospital, 2Faculty of Medicine, University Clermont 1, 3Délégation de la Recherche Clinique, Gabriel-Montpied Hospital, Clermont-Ferrand, FranceBackground: Systemic inflammation plays an important role in the increased cardiac risk observed in rheumatoid arthritis (RA). Effective control of inflammation and disease activity may be of benefit in reducing cardiovascular risk in RA patients.Objective: Our study was conducted in patients with active RA to investigate the effects of 24-week abatacept treatment on aortic stiffness measured by pulse wave velocity (PWV).Results: The study included 21 patients, of whom 17 were females, with a mean age of 65.2±13.7 years. Ten patients had positive rheumatoid factors, 16 positive anti-citrullinated protein antibodies, and 19 presented an erosive form of RA. Sixteen patients were nonresponders to anti-tumor necrosis factor-alpha treatments. After 6 months of abatacept treatment, there was a significant increase in PWV levels (9.8±2.9 versus 8.5±3.9 m/second; P=0.02). A nonsignificant increase in total cholesterol and low-density lipoprotein cholesterol was observed. There was also a significant increase in high-density lipoprotein cholesterol levels, which led to a nonsignificant decrease in atherogenic index. The improvement in disease activity was significant, and there was a decrease of systemic inflammatory parameters, but without reaching statistical significancy. Changes in PWV were significantly correlated with changes in Disease Activity Score on 28 joints based on erythrocyte sedimentation rate (r=0.46; P=0.035) and in high-density lipoprotein cholesterol (r=-0.38; P=0.046). No correlation was observed with changes in C-reactive protein and in other parameters of lipid profile or in steroid dose.Conclusion: The worsening of aortic stiffness found after 6 months of abatacept therapy might be due to an insufficient decrease in systemic inflammation.Keywords: arterial stiffness, cardiovascular risk markers, systemic inflammation, atherogenic index
format	article
author	Mathieu S Couderc M Glace B Pereira B Tournadre A Dubost JJ Soubrier M
author_facet	Mathieu S Couderc M Glace B Pereira B Tournadre A Dubost JJ Soubrier M
author_sort	Mathieu S
title	Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_short	Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_full	Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_fullStr	Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_full_unstemmed	Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_sort	effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/10caf1be94814f1781ec7ff2e9f6d82c
work_keys_str_mv	AT mathieus effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis AT coudercm effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis AT glaceb effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis AT pereirab effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis AT tournadrea effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis AT dubostjj effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis AT soubrierm effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis
_version_	1718398585351962624

Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis

Ejemplares similares